UNCY icon

Unicycive Therapeutics

0.6814 USD
+0.0435
6.82%
At close Jun 13, 4:00 PM EDT
After hours
0.6814
+0.0000
0.00%
1 day
6.82%
5 days
-11.87%
1 month
12.50%
3 months
17.02%
6 months
-4.63%
Year to date
-14.01%
1 year
4.03%
5 years
-88.35%
10 years
-88.35%
 

About: Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Employees: 22

0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

1.71% less ownership

Funds ownership: 59.44% [Q4 2024] → 57.73% (-1.71%) [Q1 2025]

6% less funds holding

Funds holding: 31 [Q4 2024] → 29 (-2) [Q1 2025]

30% less capital invested

Capital invested by funds: $49M [Q4 2024] → $34.5M (-$14.6M) [Q1 2025]

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$6
781%
upside
Avg. target
$7.50
1,001%
upside
High target
$9
1,221%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Swayampakula Ramakanth
1,221%upside
$9
Buy
Assumed
27 May 2025
Guggenheim
Vamil Divan
781%upside
$6
Buy
Initiated
21 Apr 2025
HC Wainwright & Co.
Ed Arce
1,001%upside
$7.50
Buy
Reiterated
11 Apr 2025

Financial journalist opinion

Based on 3 articles about UNCY published over the past 30 days

Neutral
GlobeNewsWire
5 days ago
Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
- The U.S. Food and Drug Administration (FDA) identified deficiencies at a third-party manufacturing vendor - FDA to provide final decision by PDUFA action date of June 28, 2025 LOS ALTOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY or the “Company”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced an update on its New Drug Application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.
Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Neutral
GlobeNewsWire
3 weeks ago
Unicycive Therapeutics to Present at Upcoming Investor Conferences
LOS ALTOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at two upcoming virtual investment conferences.
Unicycive Therapeutics to Present at Upcoming Investor Conferences
Neutral
GlobeNewsWire
3 weeks ago
Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders
LOS ALTOS, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ: UNCY) (“Unicycive” or the “Company”), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced a change in the time of the 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The previously announced date of the meeting (June 9, 2025) and location of the meeting (4300 El Camino Real, Suite 210, Los Altos, CA 94022) will not change, but the meeting will be held at 7:00 a.m., Pacific Daylight Time, on that date. Stockholders of record as of the close of business on April 30, 2025, the record date, can find additional details regarding participation in the Annual Meeting at https://annualgeneralmeetings.com/uncy2025.
Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders
Neutral
GlobeNewsWire
1 month ago
Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
- Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025
Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
Neutral
GlobeNewsWire
2 months ago
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
LOS ALTOS, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, at 2:15 p.m. ET.
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Neutral
GlobeNewsWire
2 months ago
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update
- Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025 - Commercial planning in preparation for anticipated commercial launch of OLC in late 2025 LOS ALTOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2024, and provided a business update.
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update
Neutral
GlobeNewsWire
3 months ago
Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia
LOS ALTOS, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that it will present patient reported outcomes data from its pivotal UNI-OLC-201 clinical study characterizing the potential impact of oxylanthanum carbonate (OLC) on the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.
Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia
Neutral
GlobeNewsWire
3 months ago
Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360
LOS ALTOS, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the publication of preclinical data describing the benefits of combination treatment of oxylanthanum carbonate (OLC) and tenapanor on phosphate management in the American Society of Nephrology (ASN) journal, Kidney360.
Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360
Neutral
GlobeNewsWire
4 months ago
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science
Large pill size, high pill burden and palatability were identified as key barriers for phosphate binder adherence Large pill size, high pill burden and palatability were identified as key barriers for phosphate binder adherence
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science
Neutral
GlobeNewsWire
5 months ago
Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science
LOS ALTOS, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that data from the Company's oxylanthanum carbonate (OLC) Phase 1 dose escalation study in healthy volunteers was published in the peer-reviewed journal, Clinical and Translational Science.
Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science
Charts implemented using Lightweight Charts™